StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 0.8
Power Rank trend -> Falling
03/27/2025 16:24:00 EST
Novocure Ltd (NVCR)
Industry: Medical Devices
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, NVCR has been trading in a range between $21.32 and $18.19 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Upside / Downside Potential
Novocure Ltd $NVCR entered a Red zone 1 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $36.7143, a potential upside of 99.1% from the recent price of 18.44. The stock is trading 85.09% (potential upside) below its 52 week high of $34.13 and 57.61 % (potential downside) above its 52 week low of $11.70 - based on the recent price.
Company Summary
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
News
| Prediction: Novocure (NVCR) Will Beat the Market. Here's Why Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! Source: The Motley Fool Tue, 04 Mar 2025 19:00:00 -0500 Sentiment: Positive |
| Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocure's website, www.novocure.com/investor-relations, a. Source: Business Wire Tue, 04 Mar 2025 07:00:00 -0500 Sentiment: Neutral |
| NovoCure Q4 2024 Earnings: Strong And Growing Pipeline NovoCure remains a strong buy due to robust earnings, a growing core business, and a promising pipeline, particularly in lung and pancreatic cancer treatments. Q4 2024 earnings showed strong revenue growth despite an EPS miss driven by a stock-comp event related to FDA approval. Updated DCF analysis yields a $34 price target, with Wall Street consensus at $35.83, indicating significant upside potential. Source: Seeking Alpha Fri, 28 Feb 2025 13:10:18 -0500 Sentiment: Positive |
| NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth NovoCure's stock has risen 42% since my October recommendation, but revenue diversification outside of glioblastoma (GBM) remains a concern. Despite FDA approvals, TTFields therapy faces adoption challenges due to marginal survival benefits and high costs, impacting market growth. NovoCure's financial health shows sufficient liquidity short-term, but profit margins will compress and S&M costs will rise in 2025. Source: Seeking Alpha Fri, 28 Feb 2025 05:17:45 -0500 Sentiment: Positive |
| NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for NovoCure (NVCR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Source: Zacks Investment Research Thu, 27 Feb 2025 11:00:16 -0500 Sentiment: Neutral |
Technicals 52 Week Hi: 34.13 52 Week Low: 11.7 Beta: 0.628 50 Day MA: 21.9437 200 Day MA: 20.5735 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.06 Qtr Revenue Growth YOY: 0.205 Forward PE: 909.0909 Trailing PE: 0